These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 36516952)

  • 1. Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study.
    Frumovitz M; Chisholm GB; Jhingran A; Ramalingam P; Flores-Legarreta A; Bhosale P; Gonzales NR; Hillman RT; Salvo G
    Am J Obstet Gynecol; 2023 Apr; 228(4):445.e1-445.e8. PubMed ID: 36516952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix.
    Frumovitz M; Munsell MF; Burzawa JK; Byers LA; Ramalingam P; Brown J; Coleman RL
    Gynecol Oncol; 2017 Jan; 144(1):46-50. PubMed ID: 27823771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved survival with bevacizumab in advanced cervical cancer.
    Tewari KS; Sill MW; Long HJ; Penson RT; Huang H; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Michael HE; Monk BJ
    N Engl J Med; 2014 Feb; 370(8):734-43. PubMed ID: 24552320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.
    Rosen VM; Guerra I; McCormack M; Nogueira-Rodrigues A; Sasse A; Munk VC; Shang A
    Int J Gynecol Cancer; 2017 Jul; 27(6):1237-1246. PubMed ID: 28448304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study.
    Tewari KS; Sill MW; Birrer MJ; Penson RT; Huang H; Moore DH; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Michael HE; Monk BJ
    Gynecol Oncol; 2023 Apr; 171():141-150. PubMed ID: 36898292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix.
    Paton F; Paulden M; Saramago P; Manca A; Misso K; Palmer S; Eastwood A
    Health Technol Assess; 2010 May; 14 Suppl 1():55-62. PubMed ID: 20507804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030).
    Grau JF; Farinas-Madrid L; Oaknin A
    Int J Gynecol Cancer; 2020 Jan; 30(1):139-143. PubMed ID: 31645423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).
    Tewari KS; Sill MW; Penson RT; Huang H; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Michael HE; DiSaia PJ; Copeland LJ; Creasman WT; Stehman FB; Brady MF; Burger RA; Thigpen JT; Birrer MJ; Waggoner SE; Moore DH; Look KY; Koh WJ; Monk BJ
    Lancet; 2017 Oct; 390(10103):1654-1663. PubMed ID: 28756902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel-carboplatin plus bevacizumab therapy for advanced neuroendocrine carcinoma of the uterine cervix: A retrospective case series.
    Kotaka S; Kondo E; Kawai Y; Okamoto K; Kishigami Y; Yamawaki T; Nagao K; Toru H; Suzuki S
    J Obstet Gynaecol Res; 2023 Dec; 49(12):2868-2874. PubMed ID: 37658751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer.
    Ilhan Y; Tatli AM; Teker F; Onder AH; Kose F; Geredeli C; Karaagac M; Kaplan MA; Inanc M; Goktas Aydin S; Kargi A; Arak H; Ozturk B; Besen AA; Selvi O; Korkmaz M; Oruc Z; Bozkurt O; Bilici A; Bayram S; Dae SA; Ozdogan M; Coskun HS; Sezgin Goksu S
    Int J Gynecol Cancer; 2022 Apr; 32(4):502-507. PubMed ID: 35086927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).
    Penson RT; Huang HQ; Wenzel LB; Monk BJ; Stockman S; Long HJ; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Method M; Michael H; Tewari KS
    Lancet Oncol; 2015 Mar; 16(3):301-11. PubMed ID: 25638326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?
    Backes FJ; Richardson DL; McCann GA; Smith B; Salani R; Eisenhauer EL; Fowler JM; Copeland LJ; Cohn DE; O'Malley DM
    Int J Gynecol Cancer; 2013 Jun; 23(5):833-8. PubMed ID: 23640292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer.
    Gass P; Thiel FC; Häberle L; Ackermann S; Theuser AK; Hummel N; Boehm S; Kimmig R; Reinthaller A; Becker S; Hilpert F; Janni W; Vergote I; Harter P; Emons J; Hein A; Beckmann MW; Fasching PA; Pöschke P;
    Gynecol Oncol; 2024 Apr; 183():25-32. PubMed ID: 38490057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triplet chemotherapy vs doublet chemotherapy plus bevacizumab in metastatic, recurrent, and persistent cervical cancer.
    Choi HJ; Lee YY; Choi CH; Kim TJ; Lee JW; Bae JH; Bae DS; Kim BG
    Curr Probl Cancer; 2020 Oct; 44(5):100557. PubMed ID: 32067746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer.
    Zighelboim I; Wright JD; Gao F; Case AS; Massad LS; Mutch DG; Powell MA; Thaker PH; Eisenhauer EL; Cohn DE; Valea FA; Alvarez Secord A; Lippmann LT; Dehdashti F; Rader JS
    Gynecol Oncol; 2013 Jul; 130(1):64-8. PubMed ID: 23591400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroendocrine carcinoma of the cervix: a systematic review of the literature.
    Tempfer CB; Tischoff I; Dogan A; Hilal Z; Schultheis B; Kern P; Rezniczek GA
    BMC Cancer; 2018 May; 18(1):530. PubMed ID: 29728073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
    Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
    Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma.
    Tiersten AD; Selleck MJ; Hershman DL; Smith D; Resnik EE; Troxel AB; Brafman LB; Shriberg L
    Gynecol Oncol; 2004 Feb; 92(2):635-8. PubMed ID: 14766258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
    Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
    Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single-arm study evaluating bevacizumab, cisplatin, and paclitaxel followed by single-agent bevacizumab in Japanese patients with advanced cervical cancer.
    Sugiyama T; Mizuno M; Aoki Y; Sakurai M; Nishikawa T; Ueda E; Tajima K; Takeshima N
    Jpn J Clin Oncol; 2017 Jan; 47(1):39-46. PubMed ID: 27803033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.